Compare · NOTV vs PPD
NOTV vs PPD
Side-by-side comparison of Inotiv Inc. (NOTV) and PPD, Inc. (PPD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NOTV and PPD operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- PPD is the larger of the two at $16.64B, about 2871.2x NOTV ($5.8M).
- NOTV has hit the wire 6 times in the past 4 weeks while PPD has been quiet.
- NOTV has more recent analyst coverage (9 ratings vs 1 for PPD).
- Company
- Inotiv Inc.
- PPD, Inc.
- Price
- $0.16+88.77%
- $47.29-0.07%
- Market cap
- $5.8M
- $16.64B
- 1M return
- -46.70%
- -
- 1Y return
- -94.58%
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 6
- 0
- Recent ratings
- 9
- 1
Inotiv Inc.
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
PPD, Inc.
PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.
Latest NOTV
- Inotiv Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Inotiv Reaches Agreement to Strengthen Capital Structure and Position Company for Future Growth
- Inotiv Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- SEC Form 3 filed by new insider Young John T. Jr.
- SEC Form 3 filed by new insider Davis Eugene I
- Inotiv Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Leadership Update, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form 10-Q filed by Inotiv Inc.
- Inotiv Inc. filed SEC Form 8-K: Other Events
- Inotiv Inc. filed SEC Form 8-K: Other Events
- Inotiv Inc. filed SEC Form 8-K: Other Events
Latest PPD
- InnoCare Pharma Goes Back to Funding Trough With STAR Market Listing
- Saama Appoints Scott Rogers as Company's Chief Financial Officer
- SEC Form 15-12B filed by PPD, Inc.
- SEC Form 4: Carlyle Group Inc. disposed of $2,646,829,818 worth of shares (55,722,733 units at $47.50)
- SEC Form SC 13G filed by PPD, Inc.
- SEC Form 4: H&F Corporate Investors Viii, Ltd. sold $6,309,960,135 worth of shares (132,841,266 units at $47.50)
- SEC Form 4: H&F Corporate Investors Vii, Ltd. sold $6,309,960,135 worth of shares (132,841,266 units at $47.50)
- SEC Form 4: Johnston David Michael returned $1,681,832 worth of shares to the company (60,929 units at $27.60) and was granted 25,522 shares, closing all direct ownership in the company
- SEC Form 4: Hill Colin returned $775,675 worth of shares to the company (16,330 units at $47.50), closing all direct ownership in the company
- SEC Form 4: Kaucic Karen returned $398,620 worth of shares to the company (31,496 units at $12.66) and was granted 23,104 shares, closing all direct ownership in the company